Toll-like receptors in immunity and inflammatory diseases: Past, present, and future

K Vijay - International immunopharmacology, 2018 - Elsevier
The immune system is a very diverse system of the host that evolved during evolution to
cope with various pathogens present in the vicinity of environmental surroundings inhabited …

New-age vaccine adjuvants, their development, and future perspective

SK Verma, P Mahajan, NK Singh, A Gupta… - Frontiers in …, 2023 - frontiersin.org
In the present scenario, immunization is of utmost importance as it keeps us safe and
protects us from infectious agents. Despite the great success in the field of vaccinology …

[HTML][HTML] Modulating Th2 cell immunity for the treatment of asthma

B León, A Ballesteros-Tato - Frontiers in immunology, 2021 - frontiersin.org
It is estimated that more than 339 million people worldwide suffer from asthma. The leading
cause of asthma development is the breakdown of immune tolerance to inhaled allergens …

Adjuvant system AS01: helping to overcome the challenges of modern vaccines

AM Didierlaurent, B Laupèze, A Di Pasquale… - Expert review of …, 2017 - Taylor & Francis
Introduction: Adjuvants are used to improve vaccine immunogenicity and efficacy by
enhancing antigen presentation to antigen-specific immune cells with the aim to confer long …

Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines

D Chatzikleanthous, DT O'Hagan… - Molecular …, 2021 - ACS Publications
Despite the many advances that have occurred in the field of vaccine adjuvants, there are
still unmet needs that may enable the development of vaccines suitable for more …

AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity

AM Didierlaurent, S Morel, L Lockman… - The Journal of …, 2009 - journals.aai.org
Abstract Adjuvant System 04 (AS04) combines the TLR4 agonist MPL (3-O-desacyl-4′-
monophosphoryl lipid A) and aluminum salt. It is a new generation TLR-based adjuvant …

Lipid A modification systems in gram-negative bacteria

CRH Raetz, CM Reynolds, MS Trent… - Annu. Rev …, 2007 - annualreviews.org
The lipid A moiety of lipopolysaccharide forms the outer monolayer of the outer membrane of
most gram-negative bacteria. Escherichia coli lipid A is synthesized on the cytoplasmic …

TLR-based immune adjuvants

F Steinhagen, T Kinjo, C Bode, DM Klinman - Vaccine, 2011 - Elsevier
This work describes the nature and strength of the immune response induced by various Toll-
like receptor ligands and their ability to act as vaccine adjuvants. It reviews the various …

Norovirus vaccine against experimental human Norwalk Virus illness

RL Atmar, DI Bernstein, CD Harro… - … England Journal of …, 2011 - Mass Medical Soc
Background Noroviruses cause epidemic and sporadic acute gastroenteritis. No vaccine is
available to prevent norovirus illness or infection. Methods We conducted a randomized …

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4

V Mata-Haro, C Cekic, M Martin, PM Chilton… - Science, 2007 - science.org
The inflammatory toxicity of lipopolysaccharide (LPS), a component of bacterial cell walls, is
driven by the adaptor proteins myeloid differentiation factor 88 (MyD88) and Toll-interleukin …